Application Note: Genome Analysis

pdxBlacklist: Identifying artefactual variants in patient-derived xenograft samples

Max Salm^{1*}, Sven-Eric Schelhorn², Lee Lancashire¹ and Thomas Grombacher²

¹Intellectual Property & Science, Clarivate Analytics, Friars House, Blackfriars Road, London SE1 8EZ, UK.

²Global Early Development/ Quantitative Pharmacology & Drug Disposition, Merck KGaA, Darmstadt, Germany.

*To whom correspondence should be addressed.

Summary

Patient-derived tumor xenograft (PDX) samples typically represent a mixture of mouse and human tissue. Variant call sets derived from sequencing such samples are commonly contaminated with false positive variants that arise when mouse-derived reads are mapped to the human genome. *pdxBlacklist* is a novel approach designed to rapidly identify these false-positive variants, and thus significantly improve variant call set quality.

Availability: *pdxBlacklist* is freely available on GitHub: <https://github.com/MaxSalm/pdxBlacklist>

Contact: maxsalm3@gmail.com

Supplementary information: Supplementary data are available.

1 Introduction

Patient-derived tumor xenografts (PDXs) are emerging as key preclinical models in oncology research and drug development (Day *et al.*, 2015). PDX models faithfully reflect the molecular characteristics of the source tumour (Tentler *et al.*, 2012) and thus can be used to address diverse subjects such as tumour heterogeneity, evolutionary dynamics and treatment-resistance (Byrne *et al.*, 2017). To this end, major PDX consortia are generating comprehensive molecular profiling data for thousands of models using next generation sequencing (Gao *et al.*, 2015; Bult *et al.*, 2015; Byrne *et al.*, 2017). However, assay sensitivity and specificity is routinely compromised by contaminating mouse DNA and RNA (Lin *et al.*, 2010; Rossello *et al.*, 2013). To limit the technical artifacts caused by sequencing a mixture of two species, each sequence read can be assigned to a source species by comparative alignment to both human and mouse genomes (Conway *et al.*, 2012; Ahdesmäki *et al.*, 2016). However, such read disambiguation imposes a significant computational burden and may be confounded by homologous human-mouse loci (Tso *et al.*, 2014). To complement this strategy and provide an efficient alternative, we developed the *pdxBlacklist* approach for DNA variant calls.

tions to match in-house PDX processing pipelines. The *pdxBlacklist* pipeline is implemented using the *Ruffus* framework (Goodstadt, 2010). For the analysis presented herein, a blacklist was created by processing whole genome sequencing data generated for the Mouse Genomes Project for 18 mouse strains (Keane *et al.*, 2011). Alignment to the hg19 genome build was performed by *BWA-MEM* (Li, 2014), and variants were called using *VarDict* (Lai *et al.*, 2016): this generated a false positive dataset comprising 11,119,424 SNVs, 13,77,355 indels and 2,305,881 complex variants.

2 Approach

pdxBlacklist ingests aligned mouse-derived sequencing reads, realigns these to the human genome and outputs a list of artefactual variants resulting from cross-species mapping errors. Once this ‘blacklist’ of *de facto* false positives has been created, it can be used to filter out mouse-related artifacts and refine any PDX variant dataset. Alignment and variant calling are managed by the *bcbio* best-practice variant calling pipelines; this facilitates blacklist generation for diverse variant types (e.g. SNV, indel and SV) and enables genome/aligner/caller combina-

3 Application

To demonstrate the importance of accounting for mouse-derived artifacts in PDX studies, a *pdxBlacklist*-derived blacklist was employed in three scenarios. First, the blacklist was compared to a public variant database (the COSMIC catalogue (v67) (Forbes et al., 2017)) which identified 41,675 SNVs that may be PDX artifacts (e.g. COSM1599955 from a glioblastoma PDX study (Yost et al., 2013)). Secondly, the blacklist was used to annotate variants called from 8 synthetic PDX samples that simulate increasing proportions of mouse contamination (Supplementary Figure 1). As expected, the number of blacklist variants detected was strongly correlated with mouse genome contamination ($r(6)=0.99$, $p = 2.6e-06$). Interestingly, a specific variant class was enriched amongst the detected artifacts (CA>TG/TG>CA dinucleotide substitutions). Finally, this blacklist was used to annotate whole exome sequencing derived variant data generated for 300 PDXs, produced using the same analytical pipeline but optionally including read disambiguation by *Disambiguate* (Ahdesmäki et al., 2016). Of the 3,670,468 PDX variants, 83% (3,057,911) are annotated as false positive variants by both *Disambiguate* and *pdxBlacklist*. Despite the considerable redundancy between tools, 122,594 and 12,749 variants are filtered specifically by *Disambiguate* or *pdxBlacklist* respectively (Supplementary Figure 2). Importantly, 111 of the *pdxBlacklist* specific variants are non-synonymous SNVs in Cancer Gene Census members.

4 Discussion

pdxBlacklist generates false positive variant “blacklists” that can be used to significantly improve confidence in variant calls derived from PDXs. As illustrated, this method is comparable to read disambiguation in sensitivity but offers a significant improvement in performance once a blacklist has been generated. Moreover by using an annotation-based approach, *pdxBlacklist* offers a soft filter rather than a hard filter (as is implicit in *Disambiguate*), and this can be applied to existing PDX variant datasets retrospectively without recourse to the original sequencing reads. Finally, as demonstrated in the final benchmarking exercise, the *pdxBlacklist* output identifies false positive variants masquerading as biologically meaningful variants. To facilitate future use, the blacklist generated for this publication will be included in the *pdxBlacklist* repository. We anticipate *pdxBlacklist* to be an essential tool to serve the ever-expanding community of PDX researchers.

Conflict of Interest: none declared.

References

- Ahdesmäki, M.J. et al. (2016) Disambiguate: An open-source application for disambiguating two species in next generation sequencing data from grafted samples. *F1000Research*, 5, 2741.
- Bult, C.J. et al. (2015) Mouse tumor biology (mTB): A database of mouse models for human cancer. *Nucleic acids research*, 43, D818–D824.
- Byrne, A.T. et al. (2017) Interrogating open issues in cancer precision medicine with patient-derived xenografts. *Nature reviews. Cancer*, 17, 254–268.
- Conway, T. et al. (2012) Xenome—a tool for classifying reads from xenograft samples. *Bioinformatics (Oxford, England)*, 28, i172–i178.
- Day, C.-P. et al. (2015) Preclinical mouse cancer models: A maze of opportunities and challenges. *Cell*, 163, 39–53.
- Forbes, S.A. et al. (2017) COSMIC: Somatic cancer genetics at high-resolution. *Nucleic acids research*, 45, D777–D783.
- Gao, H. et al. (2015) High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nature medicine*, 21, 1318–1325.
- Goodstadt, L. (2010) Ruffus: A lightweight python library for computational pipelines. *Bioinformatics (Oxford, England)*, 26, 2778–2779.
- Keane, T.M. et al. (2011) Mouse genomic variation and its effect on phenotypes and gene regulation. *Nature*, 477, 289–294.
- Lai, Z. et al. (2016) VarDict: A novel and versatile variant caller for next-generation sequencing in cancer research. *Nucleic acids research*, 44, e108.
- Leinonen, R. et al. (2011) The sequence read archive. *Nucleic acids research*, 39, D19–D21.
- Li, H. (2014) Toward better understanding of artifacts in variant calling from high-coverage samples. *Bioinformatics (Oxford, England)*, 30, 2843–2851.
- Lin, M.-T. et al. (2010) Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. *BioTechniques*, 48, 211–218.
- Pedersen, B.S. et al. (2016) Vcfanno: Fast, flexible annotation of genetic variants. *Genome biology*, 17, 118.
- Rossello, F.J. et al. (2013) Next-generation sequence analysis of cancer xenograft models. *PLoS one*, 8, e74432.
- Tentler, J.J. et al. (2012) Patient-derived tumour xenografts as models for oncology drug development. *Nature reviews. Clinical oncology*, 9, 338–350.
- Tso, K.-Y. et al. (2014) Are special read alignment strategies necessary and cost-effective when handling sequencing reads from patient-derived tumor xenografts? *BMC genomics*, 15, 1172.
- Yost, S.E. et al. (2013) High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. *PLoS One*, 8, e56185.
- Zook, J.M. et al. (2014) Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. *Nature biotechnology*, 32, 246–251.

Acknowledgements

The authors wish to thank Marina Bessarabova and Eike Staub for helpful discussions and comments.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Author contributions

MS authored the *pdxBlacklist* algorithm and the manuscript. SES & TG generated variant datasets for the PDX cohort.